Bausch + Lomb Corporation Stock Price, News & Analysis

Bausch + Lomb (NYSE/TSX: BLCO) announced that CFO Sam Eldessouky will participate in the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 7:35 a.m. ET in New York City. Investors can access a live webcast of the conference through the company's Investor Relations website. Bausch + Lomb is a global eye health company focused on helping people improve their vision and quality of life.

Bausch + Lomb (NYSE/TSX: BLCO) held its 2025 Annual Meeting of Shareholders on May 21, 2025, where shareholders elected all 10 nominated directors to the board. The meeting resulted in strong approval rates for all nominees, with each director receiving over 337 million votes in favor.

Additionally, shareholders approved several other key measures including: a non-binding advisory vote on executive compensation, the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2026 Annual Meeting, and authorization for the board to determine the auditor's remuneration.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Zenlens CHROMA HOA scleral contact lenses in the United States. This innovative product is designed to correct advanced higher-order aberrations (HOA) using custom, wavefront-guided scleral lens technology. The lenses utilize proprietary technologies including SmartCurve™ and Bi-Elevation™ to achieve secure lens fit and reduce visual distortions.

The company is partnering with Advance Medical and OVITZ® for implementation, utilizing Advance Medical's FocalPoints® software platform for manufacturing and OVITZ's xwave aberrometer for measurement. The technology aims to enhance vision quality and improve clarity by reducing symptoms such as halos and glare, particularly benefiting patients with complex corneal irregularities.

Bausch + Lomb (NYSE/TSX: BLCO) has received CE Mark approval for its LuxLife full range of vision intraocular lens (IOL), a preloaded lens designed to provide natural, continuous vision from distance to near. Clinical studies demonstrated excellent outcomes, with 95.6% of patients reporting spectacle independence at intermediate distance and 89.5% at near.

The LuxLife IOL features Pure Refractive Optics (PRO) Technology and Allied Ray Technology (ART) Zones, ensuring no light loss to the retina unlike diffractive IOLs. The lens offers cylinders from +0.75D to +6.00D, addressing 79.5% of patients with corneal astigmatism prior to cataract surgery. Commercial availability in Europe is expected in the coming weeks, with a toric version to follow.

Bausch + Lomb reported Q1 2025 financial results with revenue of $1.137 billion, showing 3% growth as reported and 5% on a constant currency basis compared to Q1 2024. The company faced challenges, recording a GAAP net loss of $212 million and adjusted EBITDA of $126 million.

Key segment performance:

• Vision Care: $656M revenue, up 3%
• Surgical: $214M revenue, up 9%
• Pharmaceuticals: $267M revenue, flat

The company updated its 2025 guidance due to the enVista intraocular lenses recall, projecting revenue between $5.0-5.1B with 4.5-6.5% constant currency growth. The recall is expected to impact revenue by ~$55M and adjusted EBITDA by ~$65M. Despite challenges, growth was driven by Daily SiHy lenses, LUMIFY, and surgical equipment sales.

Bausch + Lomb (NYSE/TSX: BLCO) has announced the return of enVista® intraocular lenses (IOLs) to market following their voluntary recall. The company has identified that the recall was caused by raw material from a different vendor in certain lots, showing a clear correlation with reported toxic anterior segment syndrome (TASS) cases.

Following a comprehensive investigation conducted with a TASS expert and an advisory group of nearly 30 leading cataract surgeons, Bausch + Lomb has implemented enhanced inspection protocols and stricter standards for monomer preparation by vendors. The company has resumed full production of all enVista IOLs and plans to restore full market supply in the U.S. in the coming weeks.

Market reentry in other countries will be determined through collaboration with local health authorities. Financial impacts of the recall will be discussed during the company's first-quarter earnings call on April 30.

Bausch + Lomb (NYSE/TSX: BLCO) has achieved a significant environmental milestone through its recycling initiatives. The company's ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collectively gathered 103,169,500 units (625,026 pounds) of used contact lenses, eye care, and lens care materials in the United States - equivalent to 600 concert grand pianos.

The ONE by ONE program, launched in November 2016, has collected over 101 million used contact lenses, blister packs, and top foils. The Biotrue Eye Care Recycling program, initiated in April 2021, has accumulated more than 1.3 million eye drop single dose units, lens cases, lens solution caps, and Biotrue-branded eye drop bottles.

This initiative addresses a critical environmental concern, as an estimated 6-10 metric tons of contact lenses end up in wastewater annually in the U.S., potentially affecting aquatic environments and the human food supply. The programs provide a solution for efficiently processing these materials, which are typically challenging to recycle through standard facilities.